Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,885
  • Shares Outstanding, K 9,462
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,290 K
  • 60-Month Beta 1.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.71
Trade SLS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +188,590.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.46 +4.07%
on 10/02/20
2.83 -9.54%
on 10/23/20
-0.09 (-3.40%)
since 09/30/20
3-Month
1.76 +45.45%
on 09/04/20
4.43 -42.21%
on 07/31/20
-0.65 (-20.25%)
since 07/30/20
52-Week
1.46 +75.95%
on 04/03/20
10.89 -76.49%
on 11/05/19
-3.93 (-60.59%)
since 10/30/19

Most Recent Stories

More News
SELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range...

SLS : 2.56 (-2.66%)
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results

- Strengthened balance sheet in August 2020 with $9.2 million private placement priced at-the-market -

SLS : 2.56 (-2.66%)
SELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range...

SLS : 2.56 (-2.66%)
Targeting The National Cancer Institute's #1- Ranked Cancer Antigen: SELLAS' Most Advanced Immunotherapy in Pivotal Phase 3 Study in AML and in Phase 1/2 Studies in Combination With PD1

New York, New York--(Newsfile Corp. - June 23, 2020) - As the United States enters nearly its fifth month in the global fight against COVID-19, many investors have set their eyes on companies racing to...

SLS : 2.56 (-2.66%)
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

The Virtual Summer Summit will take place on June 9-12, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below...

ACCO : 5.27 (-5.56%)
ALIM : 4.24 (+1.07%)
ANVS : 4.56 (-6.56%)
AQB : 3.80 (-3.80%)
ARTL : 0.4578 (-8.35%)
AVLNF : 0.0544 (-1.09%)
BLCM : 3.71 (-37.12%)
NDRA : 0.6875 (-4.26%)
EFOI : 6.54 (-2.82%)
EQ : 6.35 (+5.83%)
EXROF : 1.6800 (+1.20%)
HL : 4.58 (-0.65%)
HSII : 22.85 (+0.09%)
HSDT : 0.3819 (-4.50%)
HGBL : 1.7000 (-5.56%)
IPWR : 5.47 (-3.70%)
LINC : 4.67 (-3.91%)
MBII : 1.1000 (-3.51%)
MLSS : 1.5400 (-1.91%)
MYSZ : 0.9561 (-1.96%)
NBEV : 2.34 (-5.65%)
ONCS : 3.79 (-1.04%)
OGEN : 0.4719 (-9.18%)
SFE : 5.82 (-0.17%)
SLS : 2.56 (-2.66%)
PIXY : 2.12 (-5.78%)
SGLB : 2.10 (-5.41%)
SOTK : 3.8500 (unch)
TNXP : 0.5619 (-6.75%)
TGA : 0.3854 (+0.50%)
URG : 0.4556 (+5.83%)
SELLAS to Host Virtual Annual Meeting of Stockholders

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range...

SLS : 2.56 (-2.66%)
SELLAS Establishes Independent Data Monitoring Committee of Leading Clinical and Biostatistics Experts for Pivotal Phase 3 REGAL Clinical Trial

-- Moshe Talpaz, M.D., Associate Director of Translational Research and Associate Chief of the Division of Hematology/Oncology at the University of Michigan Comprehensive Cancer Center to serve as DMC...

SLS : 2.56 (-2.66%)
SELLAS Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range...

SLS : 2.56 (-2.66%)
SELLAS to Present at UBS Virtual Global Healthcare Conference

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range...

SLS : 2.56 (-2.66%)
SELLAS Releases Annual Letter to Shareholders

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range...

SLS : 2.56 (-2.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present...

See More

Key Turning Points

2nd Resistance Point 2.75
1st Resistance Point 2.65
Last Price 2.56
1st Support Level 2.49
2nd Support Level 2.43

See More

52-Week High 10.89
Fibonacci 61.8% 7.29
Fibonacci 50% 6.17
Fibonacci 38.2% 5.06
Last Price 2.56
52-Week Low 1.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar